Short report: Differentiation of patients with leprosy from non-infected individuals by the chemokine eotaxin/CCL11

American Journal of Tropical Medicine and Hygiene

Volumn 77, Issue 3, 2007, Pages 547-550

  Mendonça, Vanessa A ^a,b   Malaquias, Luiz C ^c   Brito Melo, Gustavo E ^b   Castelo Branco, Alexandre ^d   Antunes, Carlos M ^a   Ribeiro, Antonio L ^a   Teixeira, Mauro M ^a   Teixeira, Antonio L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDADE FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI   (Brazil)

^c UNIVERSIDADE VALE DO RIO DOCE   (Brazil)

^d Secretaria Municipal de Educação de Governador Valadares   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; BETA CHEMOKINE; CCL3 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEPROSY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; BLOOD; LABORATORY DIAGNOSIS; SENSITIVITY AND SPECIFICITY;

CHEMOKINES, CC; FALSE POSITIVE REACTIONS; HUMANS; LEPROSY; SENSITIVITY AND SPECIFICITY;

EID: 35748959043     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2007.77.547     Document Type: Article

References (21)

1. World Health Organization, 2002. Leprosy global situation. Wkly Epidemiol Rec 77: 1-8.
2. Britton WJ, Lockwood DNJ, 2004. Leprosy. Lancet 363: 1209-1219.
3. Agrawal A, Pandit L, Dalal M, Shetty JP, 2005. Neurological manifestations of Hansen's disease and their management. Clin Neurol Neurosurg 107: 445-454.
4. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL, 2006. The continuing challenges of leprosy. Clin Microbiol Rev 19: 338-381.
5. Lockwood DN, 2002. Leprosy elimination: a virtual phenomenon or a reality. BMJ 324: 1516-1518.
6. Klatser PR, Wit MY, Fajardo TT, Cellona RV, Abalos RM, de la Cruz EC, Madarang MG, Hirsch DS, Douglas JT, 1989. Evaluation of Mycobacterium leprae antigens in the monitoring of a dapsone-based chemotherapy of previously untreated lepromatous patients in Cebu, Philippines. Lepr Rev 60: 178-186.
7. Buhrer-Sekula S, Smits HL, Gussenhoven GC, van Leeuwen J, Amador S, Fujiwara T, Klatser PR, Oskam L, 2003. Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy. J Clin Microbiol 41: 1991-1995.
8. Kasahara K, Tobe T, Tomita M, Mukaida N, Shao-Bo S, Matsushima K, Yoshida T, Sugihara S, Kobayashi K, 1994. Selective expression of monocyte chemotactic and activating factor/ monocyte chemoattractant protein 1 in human blood monocytes by Mycobacterium tuberculosis. J Infect Dis 170: 1238-1247.
9. Agostini C, Cassatella M, Zambello R, Trentin L, Gasperini S, Perin A, Piazza F, Siviero M, Facco M, Dziejman M, Chilosi M, Qin S, Luster AD, Semenzato G, 1998. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 161: 6413-6420.
10. Ritter U, Moll H, Laskay T, Brocker E, Velazco O, Becker I, Gillitzer R, 1996. Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis. J Infect Dis 173: 699-709.
11. Sadek I, Sada E, Toosi Z, Schwander SK, Rich EA, 1998. Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am J Respir Crit Care Med 19: 513-521.
12. Hasan Z, Zaidi I, Jamil B, Khan MA, Kanji A, Hussain R, 2005. Elevated ex vivo monocyte chemotactic protein-1 (CCL2) in pulmonary as compared with extra-pulmonary tuberculosis. BMC Immunol 6: 14.
13. Alessandri AL, Souza AL, Oliveira SC, Macedo GC, Teixeira MM, Teixeira AL, 2006. Concentrations of CXCL8, CXCL9 and sTNFr1 in plasma of patients with pulmonary tuberculosis undergoing treatment. Inflamm Res 55: 528-533.
14. World Health Organization, 1997. A Guide to Eliminating Leprosy as a Public Health Problem. Second edition. Geneva: World Health Organization. WHO/LEP/97.7.
15. World Health Organization , 1998. Expert Committee on Leprosy, 7th Report. Geneva: World Health Organization.
16. Hanley JA, McNeil BJ, 1983. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843.
17. Hasan Z, Mahmood A, Zafar S, Khan A, Hussian R, 2004. Leprosy patients with lepromatous disease have an up-regulated IL-8 response that is unlinked to TNFa responses. Int J Lepr Other Mycobact Dis 72: 35-44.
18. Stefani MMA, Martelli CMT, Gillis TP, Krahenbuhl JL and the Brazilian Leprosy Study Group, 2003. In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression. J Infect Dis 188: 1024-1031.
19. Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ, 2002. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of Mycobacterial infection. J Immunol 168: 4620-4627.
20. Bandeira-Melo C, Herbst A, Weller PF, 2001. Eotaxins: contributing to the diversity of eosinophil recruitment and activation. Am J Respir Cell Mol Biol 24: 653-657.
21. Gutierrez-Ramos JC, Lloyd C, Gonzalo JA, 1999. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunol Today 20: 500-504.